Loading company
$4.88+0.2%Nov 10 close
Next earnings: December 21, 2026
Figures through July 31, 2026, from the 10-Q filed September 11, 2026
Past performance
- 1W
- +1.9%
- 1M
- +1.5%
- 3M
- -3.7%
- 6M
- -21.4%
- 1Y
- -28.2%
- 5Y
- -51.8%
$4.88+0.2%Nov 10 close
Next earnings: December 21, 2026
Figures through July 31, 2026, from the 10-Q filed September 11, 2026
Champions Oncology, Inc. is scheduled to report next on December 21, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending July 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 31, 2026 | 3 months toJul 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $15.2M | $14M | +8.84% |
| Profit | -$426K | -$466K | +8.58% |
| Free Cash Flow | -$547K | $554K | -198.74% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Champions Oncology, Inc. has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Champions Oncology, Inc.’s Item 2.02 8-K filed September 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.